Eagle Pharmaceuticals Announces 2025 Annual Meeting Date
Eagle Pharmaceuticals (OTCMKTS: EGRX) has announced its 2025 Annual Meeting of Stockholders will be held on October 17, 2025. The company has set August 18, 2025 at 5 p.m. Eastern Time as the record date for stockholder participation. Specific details regarding the meeting time and location will be communicated directly to eligible stockholders through official meeting materials.
Eagle Pharmaceuticals (OTCMKTS: EGRX) ha comunicato che la sua Assemblea Annuale degli Azionisti 2025 si terrà il 17 ottobre 2025. La società ha stabilito il 18 agosto 2025 alle 17:00 ora orientale come data di riferimento per la partecipazione degli azionisti. I dettagli relativi all'orario e alla sede verranno inviati direttamente agli azionisti aventi diritto tramite i materiali ufficiali della riunione.
Eagle Pharmaceuticals (OTCMKTS: EGRX) ha anunciado que su Junta Anual de Accionistas 2025 se celebrará el 17 de octubre de 2025. La compañía ha fijado el 18 de agosto de 2025 a las 5:00 p.m., hora del Este, como la fecha de registro para la participación de los accionistas. Los detalles sobre la hora y el lugar se comunicarán directamente a los accionistas elegibles mediante los materiales oficiales de la reunión.
Eagle Pharmaceuticals (OTCMKTS: EGRX)는 2025년 연례 주주총회를 2025년 10월 17일에 개최한다고 발표했습니다. 회사는 주주 참여를 위한 기준일을 동부 표준시 기준 2025년 8월 18일 오후 5시로 정했습니다. 회의의 구체적인 시간과 장소는 공식 회의 자료를 통해 자격 있는 주주에게 직접 안내될 예정입니다.
Eagle Pharmaceuticals (OTCMKTS: EGRX) a annoncé que son Assemblée annuelle des actionnaires 2025 se tiendra le 17 octobre 2025. La société a fixé le 18 août 2025 à 17h00, heure de l'Est, comme date d'enregistrement pour la participation des actionnaires. Les détails concernant l'heure et le lieu seront communiqués directement aux actionnaires éligibles via les documents officiels de la réunion.
Eagle Pharmaceuticals (OTCMKTS: EGRX) hat angekündigt, dass seine Jahreshauptversammlung 2025 am 17. Oktober 2025 stattfinden wird. Das Unternehmen hat den 18. August 2025 um 17:00 Uhr Eastern Time als Stichtag für die Teilnahme der Aktionäre festgelegt. Konkrete Angaben zu Uhrzeit und Ort werden berechtigten Aktionären direkt über die offiziellen Versammlungsunterlagen mitgeteilt.
- None.
- None.
WOODCLIFF LAKE, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that its 2025 Annual Meeting of Stockholders (the “2025 Annual Meeting”) will be held on October 17, 2025. The specific time and place for the 2025 Annual Meeting will be specified in a notice and meeting materials to be provided to stockholders of record as of 5 p.m. Eastern Time on August 18, 2025, which is the record date for the meeting.
The Company’s bylaws establish certain procedural requirements and deadlines that are applicable to annual stockholder meetings, including the 2025 Annual Meeting. A copy of the bylaws can be found at the following link: Eagle Bylaws.
About Eagle Pharmaceuticals, Inc.
Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients’ lives. Eagle’s commercialized products include PEMFEXY®, RYANODEX®, BENDEKA®, BELRAPZO®, TREAKISYM® (Japan), and BYFAVO® and BARHEMSYS® through its wholly owned subsidiary Acacia Pharma Inc. Eagle’s oncology and critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states, and the company is focused on developing medicines with the potential to become part of the personalized medicine paradigm in cancer care.
Investor Relations Contact
Lisa M. Wilson
T: 212-452-2793
E: lwilson@insitecony.com
